Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Net Income From Continuing Operations : ¥2,204 Mil (TTM As of Mar. 2025)

View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tianjin Pharmaceutical Da Ren Tang Group's net income from continuing operations for the three months ended in Mar. 2025 was ¥372 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ¥2,204 Mil.

Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

679.66

786.88

873.26

968.71

2,215.22

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															383.38	267.79	141.96	1,422.08	371.79

Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,204 Mil.

Tianjin Pharmaceutical Da Ren Tang Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

T14:Singapore 2TZ:Germany

Address

No. 17 Baidi Road, Da Ren Tang Mansion, Nankai District, Tianjin, CHN, 300193

Website

https://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Executives

Li Li Qun	Director
Ni Zhen Guo	senior management
Yu Hong	Directors, senior managers
Zhou Hong	Directors, senior managers
Zhang Jian	senior management
Niu Sheng Fang	senior management
Wang Xin	senior management
Wang Mai	Director
Jiao Yan	senior management
Hao Fei Fei	Director
Zhang Bao Tong	senior management
Wang Zhi Qiang	senior management
Liang Xiu Qin	senior management
Li Jia Sheng	Supervisors
Zhang Hong Kui	Director

Tianjin Pharmaceutical Da Ren Tang Group Headlines

No Headlines